Paul S. Horn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul S. Horn has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Amadeo J Pesce
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267-0714
4 shared publications- Amadeo Pesce
Millennium Laboratories Research Institute, San Diego, CA 92127, USA
3 shared publications Bradley E Copeland
Department of Pathology and Laboratory Medicine, College of Medicine, and
2 shared publications- Bridgit Crews
Millennium Laboratories, San Diego, California 92127, USA
2 shared publications - Cameron West
From the Millennium Laboratories Research Institute, San Diego, CA
2 shared publications - Charles Mikel
Millennium Laboratories Research Center, San Diego, California 92127, USA
2 shared publications
Latest Publications
- 18 April 2016
- Published by Taylor & Francis in Communications in Statistics - Theory and Methods
- Vol. 45 (10) , 2810-2833
A low-end quantile estimator from a right-skewed distribution
In many statistical applications estimation of population quantiles is desired. In this study, a log–flip–robust (LFR) approach is proposed to estimate, specifically, lower-end quantiles (those below the median) from a continuous, positive, right-skewed distribution. Characteristics of common right-skewed distributions suggest that a logarithm transformation (L) followed by flipping the lower half of the sample (F) allows for the estimation of the lower-end quantile using robust methods (R) based on symmetric populations. Simulations show that this approach is superior in many cases to current methods, while not suffering from the sample size restrictions of other approaches.
- 18 April 2016
- Published by Taylor & Francis in Communications in Statistics - Theory and Methods
- Vol. 45 (10) , 2810-2833
A low-end quantile estimator from a right-skewed distribution
In many statistical applications estimation of population quantiles is desired. In this study, a log–flip–robust (LFR) approach is proposed to estimate, specifically, lower-end quantiles (those below the median) from a continuous, positive, right-skewed distribution. Characteristics of common right-skewed distributions suggest that a logarithm transformation (L) followed by flipping the lower half of the sample (F) allows for the estimation of the lower-end quantile using robust methods (R) based on symmetric populations. Simulations show that this approach is superior in many cases to current methods, while not suffering from the sample size restrictions of other approaches.
- 18 March 2011
- Vol. 14 (2) , 189-93
Illicit drug use in the pain patient population decreases with continued drug testing.
A major concern of physicians treating pain patients with chronic opioid therapy and similar drugs is determining whether the patients are also using illicit drugs. This is commonly determined by urine drug testing (UDT). However, there are few studies on whether or not monitoring patients by this technique decreases illicit drug use. To determine if the presence of illicit drugs decreases over a number of physician visits where UDT was performed. The method involved a retrospective study of tests for the illicit drugs marijuana, cocaine, methamphetamine, ecstacy (MDMA) phencyclidine (PCP) and the heroin metabolite, 6-acetylmorphine as confirmed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). A database of 150,000 patient visits was examined for the presence of any of these 6 drugs. A total of 87,000 patients were initially tested. The number of patients who were repeatedly tested decreased over time. The percentage of patients positive for any of these illicit drugs decreased from 23% to 9% after 14 visits where UDT was performed. When graphed there was a trend to decreasing use. The Spearman correlation = -0.88, p < 0.0001. The major illicit drug was marijuana. When this was removed from the analysis, there was an even greater correlation with decreased illicit drug use. Spearman correlation = -0.92 (p < 0.0001) using a weighted correlation. Patients continuing to use illicit drugs might be dismissed from practices thus biasing the study towards illicit drug avoidance. Continued UDT might decrease illicit drug use among pain patients.
- 18 March 2011
- Vol. 14 (2) , 189-93
Illicit drug use in the pain patient population decreases with continued drug testing.
A major concern of physicians treating pain patients with chronic opioid therapy and similar drugs is determining whether the patients are also using illicit drugs. This is commonly determined by urine drug testing (UDT). However, there are few studies on whether or not monitoring patients by this technique decreases illicit drug use. To determine if the presence of illicit drugs decreases over a number of physician visits where UDT was performed. The method involved a retrospective study of tests for the illicit drugs marijuana, cocaine, methamphetamine, ecstacy (MDMA) phencyclidine (PCP) and the heroin metabolite, 6-acetylmorphine as confirmed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). A database of 150,000 patient visits was examined for the presence of any of these 6 drugs. A total of 87,000 patients were initially tested. The number of patients who were repeatedly tested decreased over time. The percentage of patients positive for any of these illicit drugs decreased from 23% to 9% after 14 visits where UDT was performed. When graphed there was a trend to decreasing use. The Spearman correlation = -0.88, p < 0.0001. The major illicit drug was marijuana. When this was removed from the analysis, there was an even greater correlation with decreased illicit drug use. Spearman correlation = -0.92 (p < 0.0001) using a weighted correlation. Patients continuing to use illicit drugs might be dismissed from practices thus biasing the study towards illicit drug avoidance. Continued UDT might decrease illicit drug use among pain patients.
- 25 May 2010
- Vol. 13 (3) , 283-7
Marijuana correlates with use of other illicit drugs in a pain patient population.
A significant number of chronic pain patients may use marijuana. Physicians treating those patients can benefit by knowing whether their patients using marijuana are at higher risk for using other illicit drugs such as cocaine and/or methamphetamine. Our objective was to determine whether marijuana-using chronic pain patients have a higher incidence of cocaine and/or methamphetamine use. A retrospective study of the incidence of pain patients using marijuana and/or other illicit drugs such as methamphetamine and cocaine versus the incidence of pain patients not using marijuana but using methamphetamine and/or cocaine. Urine specimens from chronic pain patients were analyzed by LC-MS/MS to determine the co-occurrence of these abused substances. In this study 21,746 urine specimens were obtained from chronic pain patients. We found a 13.0% incidence of patients positive for the acid form of Tetrahydrocannabinol (THCA). The percentage of those positive for cocaine was 4.6%, those positive for methamphetamine totaled 1.07%. Using both chi-square and a Logistic Regression analysis, we determined that there was a correlation between marijuana use and the use of other illicit drugs. The odds ratio was > 3.7 for other illicit drug use. The study is limited in that we obtained no data as to the causal relationships of this type of drug use. Pain physicians should be aware that this relationship exists and marijuana-using patients are at greater risk for use of other illicit drugs although no causal relationship is implied. Increased monitoring of these patients may help minimize potential morbidity due to drug interactions as well as identify patients who may be diverting prescriptions in order to pay for illicit drugs.
- 25 May 2010
- Vol. 13 (3) , 283-7
Marijuana correlates with use of other illicit drugs in a pain patient population.
A significant number of chronic pain patients may use marijuana. Physicians treating those patients can benefit by knowing whether their patients using marijuana are at higher risk for using other illicit drugs such as cocaine and/or methamphetamine. Our objective was to determine whether marijuana-using chronic pain patients have a higher incidence of cocaine and/or methamphetamine use. A retrospective study of the incidence of pain patients using marijuana and/or other illicit drugs such as methamphetamine and cocaine versus the incidence of pain patients not using marijuana but using methamphetamine and/or cocaine. Urine specimens from chronic pain patients were analyzed by LC-MS/MS to determine the co-occurrence of these abused substances. In this study 21,746 urine specimens were obtained from chronic pain patients. We found a 13.0% incidence of patients positive for the acid form of Tetrahydrocannabinol (THCA). The percentage of those positive for cocaine was 4.6%, those positive for methamphetamine totaled 1.07%. Using both chi-square and a Logistic Regression analysis, we determined that there was a correlation between marijuana use and the use of other illicit drugs. The odds ratio was > 3.7 for other illicit drug use. The study is limited in that we obtained no data as to the causal relationships of this type of drug use. Pain physicians should be aware that this relationship exists and marijuana-using patients are at greater risk for use of other illicit drugs although no causal relationship is implied. Increased monitoring of these patients may help minimize potential morbidity due to drug interactions as well as identify patients who may be diverting prescriptions in order to pay for illicit drugs.
- Open Access
- 9 January 2009
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 1
The association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in veterans
There is accumulating evidence for a link between trauma exposure, posttraumatic stress disorder (PTSD) and diminished health status. To assess PTSD-related biological burden, we measured biological factors that comprise metabolic syndrome, an important established predictor of morbidity and mortality, as a correlate of long-term health risk in PTSD.
- 9 January 2009
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1) , 1
Open AccessThe association of posttraumatic stress disorder and metabolic syndrome: a study of increased health risk in veterans
There is accumulating evidence for a link between trauma exposure, posttraumatic stress disorder (PTSD) and diminished health status. To assess PTSD-related biological burden, we measured biological factors that comprise metabolic syndrome, an important established predictor of morbidity and mortality, as a correlate of long-term health risk in PTSD.
- 1 June 2004
- Published by Elsevier in Clinica Chimica Acta
- Vol. 344 (1-2) , 173-179
Coenzyme Q10 changes are associated with metabolic syndrome
- 1 June 2004
- Published by Elsevier in Clinica Chimica Acta
- Vol. 344 (1-2) , 173-179
Coenzyme Q10 changes are associated with metabolic syndrome
- 1 August 2003
- Published by Elsevier in Clinica Chimica Acta
- Vol. 334 (1-2) , 5-23
Reference intervals: an update
- 1 August 2003
- Published by Elsevier in Clinica Chimica Acta
- Vol. 334 (1-2) , 5-23
Reference intervals: an update
- Open Access
- 1 October 2002
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 48 (10) , 1802-1804
Effect of Ethnicity on Reference Intervals
The clinical chemist desiring to set up appropriate reference intervals must consider race or ethnicity as a possible factor on which to subdivide an interval. The effect of ethnicity on various analyte values has not been systematically studied (1)(2). The advent of National Health and Nutrition Examination Survey (NHANES) data (3) has made it possible to determine the effect of ethnicity on reference interval estimation and whether separate reference intervals should be derived for each ethnic group.
- 1 October 2002
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 48 (10) , 1802-1804
Open AccessEffect of Ethnicity on Reference Intervals
The clinical chemist desiring to set up appropriate reference intervals must consider race or ethnicity as a possible factor on which to subdivide an interval. The effect of ethnicity on various analyte values has not been systematically studied (1)(2). The advent of National Health and Nutrition Examination Survey (NHANES) data (3) has made it possible to determine the effect of ethnicity on reference interval estimation and whether separate reference intervals should be derived for each ethnic group.
- Open Access
- 1 December 2001
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (12) , 2137-2145
Effect of Outliers and Nonhealthy Individuals on Reference Interval Estimation
Background: Improvement in reference interval estimation using a new outlier detection technique, even with a physician-determined healthy sample, is examined. The effect of including physician-determined nonhealthy individuals in the sample is evaluated. Methods: Traditional data transformation coupled with robust and exploratory outlier detection methodology were used in conjunction with various reference interval determination techniques. A simulation study was used to examine the effects of outliers on known reference intervals. Physician-defined healthy groups with and without nonhealthy individuals were compared on real data. Results: With 5% outliers in simulated samples, the described outlier detection techniques had narrower reference intervals. Application of the technique to real data provided reference intervals that were, on average, 10% narrower than those obtained when outlier detection was not used. Only 1.6% of the samples were identified as outliers and removed from reference interval determination in both the healthy and combined samples. Conclusions: Even in healthy samples, outliers may exist. Combining traditional and robust statistical techniques provide a good method of identifying outliers in a reference interval setting. Laboratories in general do not have a well-defined healthy group from which to compute reference intervals. The effect of nonhealthy individuals in the computation increases reference interval width by ∼10%. However, there is a large deviation among analytes.
- 1 December 2001
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (12) , 2137-2145
Open AccessEffect of Outliers and Nonhealthy Individuals on Reference Interval Estimation
Background: Improvement in reference interval estimation using a new outlier detection technique, even with a physician-determined healthy sample, is examined. The effect of including physician-determined nonhealthy individuals in the sample is evaluated. Methods: Traditional data transformation coupled with robust and exploratory outlier detection methodology were used in conjunction with various reference interval determination techniques. A simulation study was used to examine the effects of outliers on known reference intervals. Physician-defined healthy groups with and without nonhealthy individuals were compared on real data. Results: With 5% outliers in simulated samples, the described outlier detection techniques had narrower reference intervals. Application of the technique to real data provided reference intervals that were, on average, 10% narrower than those obtained when outlier detection was not used. Only 1.6% of the samples were identified as outliers and removed from reference interval determination in both the healthy and combined samples. Conclusions: Even in healthy samples, outliers may exist. Combining traditional and robust statistical techniques provide a good method of identifying outliers in a reference interval setting. Laboratories in general do not have a well-defined healthy group from which to compute reference intervals. The effect of nonhealthy individuals in the computation increases reference interval width by ∼10%. However, there is a large deviation among analytes.
- Open Access
- 1 December 1999
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (12) , 2284-2285
Reference Interval Computation Using Robust vs Parametric and Nonparametric Analyses
The clinical chemist is faced with the problem of defining reference intervals for many analytes. Problems that hinder such a determination are the presence of outliers in the data set and the inability to accumulate the recommended sample size ( 1). We previously have demonstrated the theoretical basis for the application of robust methods to resolve these problems ( 2). In particular, we consider the problem of establishing that the reference population is “healthy” to be a nearly impossible task because many disease processes may be missed in the examination process. Our own experience shows that diabetics were initially classified as healthy in our test population, and only after a thorough review of all of the data was it possible to elicit the presence of this disease. In this report, we propose the use of a robust estimator we have described previously ( 2). The advantage of this approach is that it is more tolerant of outliers in the reference population data and does not require as large a sample size as the nonparametric calculation method, nor does it require the reference data to be transformed to a gaussian distribution, which is not always possible. We then apply and compare this robust estimator with both the traditional nonparametric and parametric analysis in determining reference intervals for a well-studied population.
- 1 December 1999
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (12) , 2284-2285
Open AccessReference Interval Computation Using Robust vs Parametric and Nonparametric Analyses
The clinical chemist is faced with the problem of defining reference intervals for many analytes. Problems that hinder such a determination are the presence of outliers in the data set and the inability to accumulate the recommended sample size ( 1). We previously have demonstrated the theoretical basis for the application of robust methods to resolve these problems ( 2). In particular, we consider the problem of establishing that the reference population is “healthy” to be a nearly impossible task because many disease processes may be missed in the examination process. Our own experience shows that diabetics were initially classified as healthy in our test population, and only after a thorough review of all of the data was it possible to elicit the presence of this disease. In this report, we propose the use of a robust estimator we have described previously ( 2). The advantage of this approach is that it is more tolerant of outliers in the reference population data and does not require as large a sample size as the nonparametric calculation method, nor does it require the reference data to be transformed to a gaussian distribution, which is not always possible. We then apply and compare this robust estimator with both the traditional nonparametric and parametric analysis in determining reference intervals for a well-studied population.
- Open Access
- 1 March 1998
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 44 (3) , 622-631
A robust approach to reference interval estimation and evaluation
We propose a new methodology for the estimation of reference intervals for data sets with small numbers of observations or for those with substantial numbers of outliers. We propose a prediction interval that uses robust estimates of location and scale. The SAS software can be readily modified to do these calculations. We compared four reference interval procedures (nonparametric, transformed, robust with a nonparametric lower limit, and transformed robust) for sample sizes of 20, 40, 60, 80, 100, and 120 from χ2 distributions of 1, 4, 7, and 10 df. χ2 distributions were chosen because they simulate the skewness of distributions often found in clinical chemistry populations. We used the root mean square error as the measure of performance and used computer simulation to calculate this measure. The robust estimator showed the best performance for small sample sizes. As the sample size increased, the performance values converged. The robust method for calculating upper reference interval values yields reasonable results. In two examples using real data for haptoglobin and glucose, the robust estimator provides slightly smaller upper reference limits than the other procedures. Lastly, the robust estimator was compared with the other procedures in a population where 5% of the values were multiplied by a factor of 5. The reference intervals were calculated with and without outlier detection. In this case, the robust approach consistently yielded upper reference interval values that were closer to those of the true underlying distributions. We propose that robust statistical analysis can be of great use for determinations of reference intervals from limited or possibly unreliable data.
- 1 March 1998
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 44 (3) , 622-631
Open AccessA robust approach to reference interval estimation and evaluation
We propose a new methodology for the estimation of reference intervals for data sets with small numbers of observations or for those with substantial numbers of outliers. We propose a prediction interval that uses robust estimates of location and scale. The SAS software can be readily modified to do these calculations. We compared four reference interval procedures (nonparametric, transformed, robust with a nonparametric lower limit, and transformed robust) for sample sizes of 20, 40, 60, 80, 100, and 120 from χ2 distributions of 1, 4, 7, and 10 df. χ2 distributions were chosen because they simulate the skewness of distributions often found in clinical chemistry populations. We used the root mean square error as the measure of performance and used computer simulation to calculate this measure. The robust estimator showed the best performance for small sample sizes. As the sample size increased, the performance values converged. The robust method for calculating upper reference interval values yields reasonable results. In two examples using real data for haptoglobin and glucose, the robust estimator provides slightly smaller upper reference limits than the other procedures. Lastly, the robust estimator was compared with the other procedures in a population where 5% of the values were multiplied by a factor of 5. The reference intervals were calculated with and without outlier detection. In this case, the robust approach consistently yielded upper reference interval values that were closer to those of the true underlying distributions. We propose that robust statistical analysis can be of great use for determinations of reference intervals from limited or possibly unreliable data.